Tag results:

cell engineering

Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor T Cells

[Human Gene Therapy] The authors discussed the development of viral and nonviral vectors used to generate CAR-T cells, focusing on their advantages and limitations.

Orthogonal Design of Experiments for Optimization of Lipid Nanoparticles for mRNA Engineering of CAR T Cells

[Nano Letters] Sequential libraries of ionizable lipid nanoparticle formulations with varied excipient compositions were screened in comparison to a standard formulation for improved mRNA delivery to T cells with low cytotoxicity, revealing B10 as the top formulation with a 3-fold increase in mRNA delivery.

Modular Self-Assembly System for Development of Oligomeric, Highly Internalizing and Potent Cytotoxic Conjugates Targeting Fibroblast Growth Factor Receptors

[Journal of Biomedical Science] Researchers aimed to develop a modular, self-assembly system for generation of oligomeric cytotoxic conjugates, capable of FGFR1 clustering, for targeting FGFR1-overproducing cancer cells.

Genome Edited B Cells: A New Frontier in Immune Cell Therapies

[Molecular Therapy] Investigators discuss the potential of engineered B cells as a cell therapy, the challenges involved in editing the Ig locus and the advances that are making this possible, and envision future directions for this emerging field of immune cell engineering.

Engineering-Enhanced CAR T Cells for Improved Cancer Therapy

[Nature Cancer] Scientists discuss the many challenges to CAR T cell therapeutic success and innovations in CAR design and T cell engineering aimed at extending this therapeutic platform beyond hematologic malignancies.

Fate Therapeutics Announces Treatment of First Patient in Landmark Phase I Clinical Trial of FT819, the First-Ever iPSC-Derived CAR T-Cell Therapy

[Fate Therapeutics, Inc.] Fate Therapeutics, Inc. announced that the first patient has been treated with FT819, an off-the-shelf chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies. FT819 is the first-ever CAR T-cell therapy derived from a clonal master iPSC line.

Popular